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Long ncRNA Landscape in the Ileum of Treatment-Naive EarlyOnset Crohn Disease
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Background: Long noncoding RNAs (lncRNA) are key regulators of gene transcription and many show tissue-specific expression. We previously defined a novel inflammatory and metabolic ileal gene signature in treatment-naive pediatric Crohn disease (CD). We now extend our
analyses to include potential regulatory lncRNA.
Methods: Using RNAseq, we systematically profiled lncRNAs and protein-coding gene expression in 177 ileal biopsies. Co-expression analysis
was used to identify functions and tissue-specific expression. RNA in situ hybridization was used to validate expression. Real-time polymerase
chain reaction was used to test lncRNA regulation by IL-1β in Caco-2 enterocytes.
Results: We characterize widespread dysregulation of 459 lncRNAs in the ileum of CD patients. Using only the lncRNA in discovery and independent validation cohorts showed patient classification as accurate as the protein-coding genes, linking lncRNA to CD pathogenesis. Co-expression
and functional annotation enrichment analyses across several tissues and cell types 1showed that the upregulated LINC01272 is associated with
a myeloid pro-inflammatory signature, whereas the downregulated HNF4A-AS1 exhibits association with an epithelial metabolic signature. We
confirmed tissue-specific expression in biopsies using in situ hybridization, and validated regulation of prioritized lncRNA upon IL-1β exposure in
differentiated Caco-2 cells. Finally, we identified significant correlations between LINC01272 and HNF4A-AS1 expression and more severe mucosal
injury.
Conclusions: We systematically define differentially expressed lncRNA in the ileum of newly diagnosed pediatric CD. We show lncRNA utility

to correctly classify disease or healthy states and demonstrate their regulation in response to an inflammatory signal. These lncRNAs, after mechanistic exploration, may serve as potential new tissue-specific targets for RNA-based interventions.
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INTRODUCTION
The inflammatory bowel diseases (IBDs), Crohn disease
(CD) and ulcerative colitis (UC), are caused by a complex interaction between host genetic background, microbial shifts, and
environmental cues, leading to chronic activation of the mucosal
immune system.1–3 Meta-analysis identified 163 different IBD risk
loci,4 and a more recent analysis added 38 new loci.5 The majority
of those IBD susceptibility loci are intergenic or intronic. These
data are in agreement with the ENCODE project,6 showing that a
large fraction of risk for complex disease is driven by noncoding
genetic variation. Among those, approximately 10% of disease-associated single nucleotide polymorphisms (SNPs) are mapped to
genomic loci encoding long noncoding RNAs (lncRNAs).7, 8
LncRNAs play fundamental roles in gene transcription
regulation9, 10 and overall exhibit more tissue-specific expression
patterns than protein-coding genes. They are a large (>15,00011)
and diverse class of non-protein-coding genes longer than 200
nucleotides. Emerging data have highlighted their regulation of
immunity.12 LncRNA are differentially regulated in virus-infected cells13 and in monocytes after lipopolysaccharide stimulation.14 The lncRNA NeST controls susceptibility to Theiler’s
virus and Salmonella infection in mice through epigenetic regulation of the interferon-γ (IFN-γ) locus,13 and long interspersed
ncRNA (lincRNA)–Cox2 acts as a broad-acting regulatory component of a circuit that controls the inflammatory response.14
Hrdlickova et al.15 revealed lncRNA enrichment in several
immune-related disorders including IBD. Specifically, microarray analysis from colon biopsies of adults with long-standing
IBD showed widespread dysregulation of lncRNA in inflamed
and noninflamed tissue.16 However, there are no studies characterizing lncRNA in the ileum of treatment-naive (not influenced by treatment), early-onset pediatric CD patients.
The Crohn’s and Colitis Foundation of America (CCFA)–
sponsored RISK study is a prospective inception cohort study
that enrolled 1098 pediatric CD patients at diagnosis at 28 sites
in North America between 2008 and 2012.17, 18 All patients were
treatment naive, with ileal biopsies obtained during the initial
diagnostic colonoscopy. Using RISK RNAseq data and UCSC
annotation, we have previously characterized transcriptomic signatures associated with CD pathogenesis focusing on protein-coding genes.17 We defined a core ileal CD (iCD) signature enriched
for genes induced by bacterial products and pro-inflammatory
cytokine signaling, including IFNγ, whereas genes induced by
several nuclear receptors, including HNF4α, were suppressed.
Functional analyses identified enrichment of innate antimicrobial responses and a profound loss of nuclear receptor–dependent
lipid metabolic functions. However, differentially expressed lncRNAs that may play a central role in regulating the transcriptional
landscape in a tissue-specific manner have not yet been defined.
Here, we extend our analyses using GENCODE/ENCODE and
Ensembl (http://useast.ensembl.org) annotation to characterize
differentially expressed protein-coding and lncRNAs, extending the CD signature to now include 459 differentially expressed
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lncRNA genes. Importantly, we show that those lncRNAs can be
utilized to correctly classify disease or healthy states in patients
undergoing diagnostic endoscopies. We put forward a way to prioritize differentially expressed lncRNAs for future analyses, elaborate on their potential functions and tissue-specific expression,
and validate specific prioritized lncRNA expression and regulation upon IL-1β triggering. As lncRNAs show higher tissue-specific expression in comparison with protein-coding genes, these
tissue-specific lncRNA, after mechanistic exploration, may serve
as potential new targets for RNA-based interventions that will be
associated with fewer off-target toxic effects.

MATERIAL AND METHODS
The RISK Cohort
Ileal biopsy RNAseq and associated clinical information
were obtained from the RISK study,17, 19–22 an ongoing, prospective observational IBD inception cohort sponsored by the CCFA.
Newly diagnosed patients were enrolled and required to undergo
baseline colonoscopy and confirmation of characteristic chronic
active colitis/ileitis by histology before diagnosis and treatment.

RNA-seq Expression and Gene Enrichment
Analysis
Ileal RNA extraction and mRNA-seq were performed
as previously described (GEO series accession number
GSE57945),17 with some modification as noted. To include
lncRNAs in the analyses, reads were quantified by kallisto,23
using Gencode v23 as the reference genome and transcripts
per million (TPM) as an output. Only 20,326 transcripts with a
TPM above 1 in 20% of the samples were included in our downstream differential expression analysis. Samples were stratified
into specific clinical subgroups including control (Ctl) and CD
with ileal inflammation (iCD). Those groups were age- and gender-matched and were randomly assigned (ratio 4:1) to discovery or independent validation groups (Table 1). Differentially
expressed genes were determined by the moderated t test method
in GeneSpring next-generation sequencing software using the
Benjamini–Hochberg false discovery rate correction (FDR,
0.05), and analyzed for fold change differences (FC) ≥1.5. Log2transformed and baselined-to-median-level Ctl values were used
for unsupervised hierarchical clustering using the Euclidean distance metric and Ward’s linkage rule to test for groups of ileal
biopsies with similar patterns of gene expression. Pearson correlation based on trend and rate of change was performed for
selected lncRNAs as indicated for a correlation co-efficient of
0.75 < r < 1. ToppGene24 and ToppCluster25 software were used
to test for enrichment of groups of genes within biologically relevant pathways. Visualization of the network was obtained using
Cytoscape.v3.0.226 and the ReVIGO approach, which converts
a list of Gene Ontology terms into a semantic, similarity-based
scatterplot after removing redundant terms.27 LncRNA prioritization was based on at least an average of 1 TPM in Ctl or
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TABLE 1. Clinical and Demographic Characteristics

Ctl Discovery (n = 30)

CD
Discovery
(L1,L3, n = 111)

Ctl Validation
(n = 8)

CD Validation
(L1,L3, n = 28)

11.2 (3)
60
87

11.9 (3)
61
81

11 (5)
62
89

12.2 (3)
61
79

—
—
—
—

8
39
53
53

—
—
—
—

11
36
53
46

Age, mean (SD), y
Male gender, %
Mixed European descent (MED) ethnicity (3 of 4
grandparents), %
PCDAI ≤ 10 (inactive), %
PCDAI 11 to 30 (mild), %
PCDAI ≥ 31 (moderate-severe), %
Ileal deep ulcers, %

Abbreviations: L1, ileal location; L2, colon-only location; L3, ileo-colonic location; PCDAI, Pediatric Crohn Disease Activity Index at diagnosis before treatment.

iCD and showed the highest fold change differences between
iCD and Ctl. Further prioritization of the top 15 differentially
expressed lncRNAs was based on the highest number of genes
that coexpressed with the lncRNAs in our cohort. FASTQ files
from human-derived peripheral blood cells (GSE6465528) and
human-derived intestinal biopsies (E-MTAB-173329) were analyzed using the same pipeline. Similar RNA extraction, RNAseq,
and analysis pipelines were applied on the differentiated Caco-2
cells samples. Those samples’ data were deposited in GSE94578.

Caco-2 Cells
Caco-2 human colon carcinoma cell line was purchased
from the American Type Culture Collection (Manassas, VA,
USA) and maintained in standard culture conditions in DMEM
(GIBCO 41965-039, Scotland) containing 20% (v/v) heat-inactivated fetal bovine serum (GIBCO 12657-029, Scotland). For
experiments, cells were seeded on 6-well ThinCerts—0.4-um
plate (Greiner bio-one 657641, Austria) for 21 days to obtain
fully differentiated cells, and transepithelial electrical resistance
(TEER) values were measured (World Precision Instruments,
FL). Differentiated Caco-2 cells were either left untreated
or treated with 25 ng/mL of IL-1β (MerckMillipore Human
Recombinant Animal Free GF331, Germany). Cell fractionation was done using the PARIS kit (Thermo Fisher Scientific,
CA, USA) according to the manufacturer’s directions.

Expression (Quantitative Polymerase Chain
Reaction) Studies
Total RNA was isolated using Tri Reagent-LS (Sigma, T9424,
Saint Louis, MO, USA). RNA concentration and purity were
assessed on a NanoDrop ND-1000 spectrophotometer (Thermo
Fisher Scientific, Wilmington, DE, USA). First-strand cDNA
was synthesized using a high-capacity RNA-to-cDNA reverse
transcription kit (Applied Biosystems, 4387406). Quantitative realtime polymerase chain reaction (qPCR) was performed using a
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Fast SYBR Green Master mix (Applied Biosystems, 4385612) and
qPCR machine with standard qPCR parameters to analyze the
expression of indicated genes compared with the control gene
GAPDH (primer list is in Supplementary Table 10). Results were
analyzed with the comparative CT method, and log10 (relative
quantification values [Rq] values) are shown.30, 31

In Situ Hybridization
3’ end biotin-labeled probes (Integrated DNA
Technologies, Leuven, Belgium), recognizing HNF4A-AS1
and LINC01272, and a scrambled control probe were used at
180 nM for in situ hybridization on formalin-fixed, paraffin-embedded ileal biopsies. The alkaline phosphatase conjugate
streptavidin (Roche, 11093266910, Basel, Switzerland) with
subsequent BCIP/NBT color development substrate (Roche,
11681451001, Basel, Switzerland) was used to obtain the staining. A positive probe and a negative probe were included in the
assay for quality control.

Ethical Considerations
The institutional review board at each site reviewed and
approved the protocol, and informed written consent or assent
was obtained in all cases from parents or guardians. All patients
provided appropriate assent. This study was approved by national regulatory authorities and by local ethics committees or
institutional review boards.

RESULTS
Widespread Dysregulation of Protein-Coding
and lncRNAs in the Ileum of Treatment-Naive
Pediatric CD Patients Using RNAseq and
GENCODE/Ensembl Annotation
The majority of lncRNAs are generated by similar transcriptional machinery as mRNA, with a 5’ methylguanosine
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cap, and are often spliced and polyadenylated.9 We were therefore able to utilize our previously published ileal biopsy poly-A
selected RNAseq data set (GEO series accession number
GSE57945) of subjects with newly diagnosed CD and non-IBD
controls to test for differences in lncRNA expression (Table 1
and Supplementary Table 1). This includes CD patients with
clinically affected (ileal CD [iCD], n = 139) ilea and nonIBD Ctl (n = 38). CD patients and Ctl participants were randomly divided and age- and gender-matched to the discovery
(80%) and independent validation (20%) iCD and Ctl cohorts
(Table 1). However, for more comprehensive analyses of the
lncRNA, instead of using the UCSC annotation as a reference
for alignment and quantification, we used the GENCODE/
ENCODE project11 implemented into Ensembl (V23, GRCh38,
Ensembl 81) as our reference. One main advantage of using
the GENCODE/Ensembl annotation is that it clearly classifies
each annotated gene as a protein coding or noncoding gene.
The GENCODE v23 (GRCh38, Ensembl 81) version includes
60,498 genes; 19,797 protein-coding genes, 15,931 long noncoding genes, 9882 small noncoding genes, 14,477 pseudogenes,
and 411 immunoglubulin/T-cell receptor genes. For quantification, we used kallisto software.23
Our analyses comparing the iCD and Ctl ileal discovery
samples identified 3022 genes (Supplementary Table 2) that
were differentially expressed (FDR < 0.05 and fold change
≥1.5) (Supplementary Table 2 and Supplementary Fig. 1A).
Unsupervised hierarchical clustering identified groups of
patients with similar ileal gene expression profiles; this analysis
tested whether patients with CD cluster together, whereas the
transcriptional profile of non-IBD Ctl patients would cluster
together. Unsupervised hierarchical clustering of the discovery
cohorts showed that all Ctl patients grouped in cluster 1 and
most of the CD patients grouped in cluster 2 (Supplementary
Fig. 1B). We also applied principal component analysis (PCoA)
as another approach to view patients’ separation using specific
gene expression profiles, an approach that is used to reduce
dimensionality of the input data. Loading the 3022 differentially expressed genes and the top 3 dimensions showed that
most Ctl patients were separated from most of the CD patients
(Supplementary Fig. 1C). Of note, although we used Ensembl
annotation instead of the UCSC annotation that we previously used,17 we were able to show that >85% of the previously
reported genes17 are within the new 3022 genes list. However,
although our previously reported list contained <50 lncRNAs, using our current approach we identified 10 times more
lncRNAs.17

Significant Enrichment of Known IBD-Associated
SNPs Within Differentially Expressed and
Annotated lncRNA
Similar to previously reported data,16 we tested for the
presence of known IBD-associated SNPs (total of 233 SNPs)

within annotated lncRNAs. We identified IBD loci-associated
lncRNAs genes by intersecting the IBD susceptibility loci,
which was defined as a 500-kb long genomic region with the
IBD risk variant in the middle. In total, 1051 IBD loci-associated lncRNAs were identified, out of which 41 unique lncRNAs were found to be differentially expressed (Supplementary
Table 3). These differentially expressed 41 lncRNAs co-localized with 47 unique IBD risk variants, and were found to be
enriched within IBD loci (P < 0.0001, chi-square test).

LncRNAs Can Be Utilized to Correctly Classify
Disease or Healthy States in Patients Undergoing
Diagnostic Endoscopies
Classification of the 3022 genes into gene biotypes based
on GENCODE annotation is shown in Table 2 and includes
2160 protein coding genes (71%) and 459 lncRNAs (15%).
Table 2 further subdivided the lncRNAs into specific types.
Unsupervised hierarchical clustering using only the 459 lncRNAs demonstrated that all discovery Ctl samples grouped in
cluster 1 and most of the discovery CD patients grouped in
cluster 2 (Fig. 1A), similar to clustering using the entire 3022
genes (Supplementary Fig. 1). PCoA to view patients’ separation using the 459 differentially expressed lncRNAs and the
top 3 dimensions showed that most Ctl patients are separated
from most of the CD patients (Fig. 1B). Importantly, unsupervised hierarchical clustering using only the 459 lncRNAs on an
independent validation cohort also demonstrated that all Ctl
samples grouped in cluster 1 and most of the validation CD
patients grouped in cluster 2 (Fig. 1C), and PCoA showed that
most Ctl patients are separated from most of the CD patients
(Fig. 1D). Interestingly, we noted that a higher fraction of the
lncRNAs (83%, 380/459, of the lncRNAs) was downregulated

TABLE 2. Differentially Expressed Ileal Gene Types
Number of Genes
(n = 3022)

Gene Type
Protein coding genes
LncRNA

IG/TR
Pseudogenes
TEC

lncRNA type
3’ UTR overlapping
Antisense
LincRNA
Processed transcript
Sense intronic
Sense overlapping

2160
459
1
184
219
30
19
6
234
150
19

Abbreviations: IG/TR, immunoglobulin/T cell receptors; TEC, transcripts to be experimentally confirmed; UTR, untranslated region.
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FIGURE 1. Differentially expressed ileal lncRNA perform well in sample classification. A, Hierarchical clustering of the 459 differentially expressed
ileal lncRNA genes was performed on a discovery set (n = 111 iCD and 30 Ctl; fold change of ≥1.5 and corrected P < 0.05) and visualized as a heat
map with genes upregulated compared with controls in red and genes downregulated compared with controls in blue. Above the heat map, individual Ctl (blue) and iCD (red) samples are indicated. B, 459 differentially expressed lncRNA genes were used to view Ctl (blue) and iCD (red) patients’
samples, separated by training cohort, on a principal component analysis plot. C, Hierarchical clustering of the 459 differentially expressed ileal
lncRNA genes was performed on a validation cohort (n = 36) and visualized as a heat map as in (A). Above the heat map, individual Ctl (blue) and
iCD (red) samples are indicated. D, 459 differentially expressed lncRNA genes were used to view validation cohort Ctl (blue) and iCD (red) patients’
samples, on a principal component analysis plot. E, Fraction of the up- (gray) and downregulated (black) differentially expressed genes within the
459 lncRNA and 2160 protein-coding genes. A significantly higher fraction of the lncRNA were downregulated in comparison with protein coding
genes (X2 = 180.9, P < 0.001).

in iCD vs Ctl (Fig. 1E) in comparison with the fraction of the
downregulated protein-coding genes (51%, 1099/2160).
Supervised classification algorithms may be used to develop models to classify unknown patient groups based on gene
expression data that differ within a training set of known patient groups. The Support Vector Machine (SVM) algorithm is
a machine learning approach, which is commonly used to classify 2 patient classes based on differential expression of biologic
data. We conducted a supervised classification analysis using the
2160 protein-coding genes and 459 lncRNA genes differentially
expressed between iCD and Ctl on a discovery cohort comprising 111 iCD and 30 Ctl patients to develop a classification model
using the SVM algorithm (80% of the samples) (Table 1). We
then tested the accuracy of the model on an independent validation cohort of 28 iCD and 8 Ctl (Table 3). Applying the model
to the discovery and independent validation cohorts resulted
in comparable accuracy using the 459 lncRNA and 2160 protein-coding genes (Table 3). Importantly, those unsupervised
(hierarchical clustering and PCoA) and supervised (SVM algorithm) analyses of discovery and validation cohorts further link
altered expression of lncRNA to CD pathogenesis.

Prioritizing the Differentially Expressed lncRNAs Based on Highest Fold Change and
Co-expression Analyses
Our initial prioritization of differentially expressed
lncRNA was based on the highest fold change differences

TABLE 3. Accuracy of Support Vector Machine Model
on Discovery and Independent Validation Ctl and iCD
Samples
Discovery Cohort
Accuracy, %
Ctl (n = 30)
iCD (n = 111)
Overall (n = 141)
Independent Validation
Cohort Accuracy, %
Ctl (n = 8)
iCD (n = 28)
Overall (n = 36)

459 lncRNA Genes
83
98
95
459 lncRNA Genes
75
96
92

2160 ProteinCoding Genes
90
96
95
2160 ProteinCoding Genes
100
100
100

between iCD and Ctl (Tables 4 and 5) and focused on the top 15
down- and 15 upregulated ileal lncRNA. Within our pediatric
treatment-naïve cohort, we identified CDKN2B-AS1 (ANRIL)
lncRNA, previously shown to regulate gene transcription in
cis (in vicinity) and in trans (at distant loci) in carcinogenesis
and cardiovascular disease, as one of the top 15 downregulated genes. Interestingly, CDKN2B-AS1 was within the top 10
downregulated transcripts in the colon of treated adult patients
with IBD, whereas downregulation of HNF4A-AS1 lncRNA
was unique to our ileal cohort. We also identified LINC01272
and RP11-44K6.2 within our 15 top ileal upregulated lncRNAs
that were also within the top 10 upregulated lncRNA transcripts in the colon of adult IBD patients.16
Co-expression analyses32, 33 of lncRNAs with well-characterized protein-coding mRNA is usually used to gain insights
into lncRNA potential functions. As we were interested in prioritizing potential functional lncRNA, we used co-expression
as another factor for prioritization. We further prioritized the
top 15 differentially expressed lncRNAs to those that show
co-expression with the larger set of genes, as a read out for
their potential functionality. We used Pearson correlation
analyses (r > 0.75) to identify co-expression of lncRNAs
within our Ctl and iCD samples. Of the top 15 downregulated genes, both HNF4A-AS1 and CDKN2B-AS1 showed
the highest number of co-expressed genes (Table 4). The 314
HNF4A-AS1 downregulated co-expressed genes remarkably
overlapped with the 411 CDKN2B-AS1 co-expressed gene
list (>80%) and included 3 other lncRNAs (CDKN2B-AS1,
RP11-116D2.1, and RP11-132E11.2) also within the top 15
downregulated lncRNAs. Of the top 15 upregulated lncRNAs, LINC01272 showed the highest number of 187 upregulated co-expressed genes (Table 5).

Prioritized Differentially Expressed HNF4A-AS1
lncRNAs Show Epithelial-Specific Expression and
Associations With Metabolic Functions
Many lncRNAs exhibit tissue-specific expression patterns.34 We therefore assessed the expression of prioritized
LINC01272 and HNF4A-AS1 expression in independent
noninflamed tissues and cells including publically available
RNAseq of human blood–derived cell types (GSE6465528) and
human-derived intestinal tissues (E-MTAB-173329). We supplemented those analyses with RNAseq of our local differentiated
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TABLE 4. Top 15 Downregulated Differentially Expressed Ileal lncRNA Genes
Top 15 Downregulated

FC (iCD) vs Ctl

Ensembl Gene ID

lncRNA Subclass

RP11-347E10.1
FOXD1-AS1
RP11-64D22.5
RP11-91P17.1
CDKN2B-AS1

–13.2
–9.9
–8.6
–8.3
–7.4

ENSG00000254416
ENSG00000247993
ENSG00000250271
ENSG00000254001
ENSG00000240498

lincRNA
lincRNA
lincRNA
lincRNA
antisense

RP11-116D2.1
RP11-245G13.2
RP11-132E11.2
HNF4A-AS1
RP11-143A12.3
RP11-689K5.3
RP11-1223D19.1
RP11-122K13.7
RP11-798K3.2
RP11-680F8.1

–7.1
–6.8
–6.5
–6.1
–6.1
–5.9
–5.9
–5.6
–5.6
–5.5

ENSG00000261012
ENSG00000271952
ENSG00000237153
ENSG00000229005
ENSG00000250198
ENSG00000251331
ENSG00000261760
ENSG00000226699
ENSG00000259347
ENSG00000256802

lincRNA
lincRNA
lincRNA
antisense
lincRNA
lincRNA
lincRNA
antisense
lincRNA
antisense

Remark

also in adult
colon

Co-expression
97
1
35
2
411
265
1
78
314
134
1
1
1
156
200

Abbreviations: Co-expression, number of additional differentially expressed ileal genes co-expressed with the lncRNA by Pearson correlation analysis; FC, fold change between
iCD and control.

TABLE 5. Top 15 Upregulated Differentially Expressed Ileal lncRNA Genes
Top 15 Upregulated
CTB-61M7.2
RP11-598F7.3
LUCAT1
LINC01272
RP11-290L1.3
LINC00694
RP11-44K6.2
LINC01235
FAM225A
RP11-536O18.1
RP11-115D19.1
LINC00582
WISP1-OT1
RP11-638I2.8
CTD-2589M5.4

FC (iCD) vs Ctl

Ensembl Gene ID

LncRNA Subclass

16.9
11.1
10.4
9.4
7.9
6.9
5.3
5.2
5.2
4.4
4.1
4.1
4.0
4.0
4.0

ENSG00000268734
ENSG00000256948
ENSG00000248323
ENSG00000224397
ENSG00000257453
ENSG00000225873
ENSG00000253838
ENSG00000270547
ENSG00000231528
ENSG00000226197
ENSG00000251095
ENSG00000229228
ENSG00000270132
ENSG00000258666
ENSG00000255007

lincRNA
antisense
lincRNA
lincRNA
antisense
lincRNA
sense_intronic
lincRNA
lincRNA
lincRNA
antisense
antisense
sense_intronic
antisense
antisense

Remark

also in adult colon

also in adult colon

Co-expression
30
1
67
187
1
1
1
1
152
1
1
1
1
1
1

Abbreviations: Co-expression, number of additional differentially expressed ileal genes co-expressed with the lncRNA by Pearson correlation analysis; FC, fold change between
iCD and control.

Caco-2 intestinal epithelial cell lines. Caco-2 cells, although
derived from the colon, when differentiated and polarized,
exhibit a phenotype, tissue marker expression, morphology,
and cellular functions that resemble small intestine enterocytes.
Indeed, in this independent data set, we show high expression
of HNF4-AS1 in small intestinal tissue (duodenum and ileum)
and Caco-2 cells, remarkably low expression in neutrophils, and
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no expression (TPM level < 1 and read count < 10,) in other
cells and tissues (Fig. 2A).
To gain insights into those lncRNA potential functions, we employed co-expression analyses32 also in those new
samples and tested for co-expression of lncRNA with well
characterized protein-coding mRNA. We used Pearson correlation analyses (r > 0.75) to identify co-expression and then
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conducted functional annotation enrichment analyses to map
groups of related genes to identify biological process, pathways,
phenotypes, and molecular functions, where P values for the
specific pathway, phenotype, and function were obtained as
an output from ToppGene.24 Pearson correlation analyses on
those tissues and cells identified 4102 genes that co-expressed
with HNF4A-AS1 (Supplementary Table 4). Uunsupervised

hierarchical clustering for this gene set is shown in Fig. 2B,
showing clear separation between small intestine and differentiated Caco-2 cells and neutrophils. Functional annotation
enrichment analyses of those 4102 genes showed enrichment
for Gene Ontology Biological Process terms involving epithelial
development (P < 7.94E-5) and functions including the organic
acid metabolic process (P < 4.15E-13), but also enrichment for

353

Haberman
et al


Inflamm Bowel Dis • Volume 24, Number 2, February 2018

FIGURE 2. Expression and functional annotation enrichment analyses of the HNF4A-AS1 and LINC01272 co-expression networks in diverse cellular
and tissue samples. A, HNF4A-AS1 TPM levels in several human-derived noninflamed peripheral blood cells (n = 2, PBMC, B cells, T cells, neutrophil,
monocyte, NK cells, myeloid DC). Noninflamed intestinal tissues are shown (3 stomach, 2 duodenum [Duo], 4 small intestine [SI], 3 colon), and
unstimulated differentiated Caco-2 cells. B, Hierarchical clustering of the 4102 genes that co-expressed with HNF4A-AS1 (expressed above 1 TPM and
10 read count) in the indicated cells and tissues is shown and visualized as a heat map, with genes higher and lower than the median levels of all
samples in red and blue, respectively. C, The top 50 Gene Ontology (GO): Biological Process terms found for the HNF4A-AS1 co-expression network
were visualized using the ReVIGO approach, which converts a list of gene ontology terms into a semantic, similarity-based scatterplot after removing redundant terms. Bubble color indicates P value; size indicates the frequency of the GO term in the underlying GOA database (more general
terms are larger). The full list of genes and the functional enrichment results and P values are in Supplementary Table 4. D, LINC01272 TPM levels in
several human-derived peripheral blood cells and intestinal tissues are shown. E, Hierarchical clustering of the 521 genes that co-expressed with
LINC01272 (expressed above 1 TPM and 10 read count) in the indicated cells and tissues is shown and visualized as a heat map, with genes higher
and lower than the median levels of all samples in red and blue, respectively. F, Top 50 GO: Biological Process terms found for the LINC01272 co-expression network were visualized using ReVIGO approach as in (C). The full list of genes and the functional enrichment results and P values are in
Supplementary Table 5. G, RNA in situ hybridization detection of HNF4A-AS1 in paraffin-embedded sections of ileal mucosal biopsies. Dark purple
staining of HNF4A-AS1 is located predominantly in the epithelia nucleus. H, RNA in situ hybridization detection of LINC01272 in paraffin-embedded
sections of ileal mucosal biopsies. Dark purple staining of LINC01272 is located predominantly in the nucleus of immune cells scattered in the intestinal lamina propria.

ncRNA processing (P < 4.15E-13) and translation (P < 8.42E7) (Fig. 2C and Supplementary Table 4). Those results are visualized using the ReVIGO approach,27 which converts a list of
Gene Ontology terms into a semantic, similarity-based scatterplot after removing redundant enrichment terms.

Prioritized Differentially Expressed LINC01272
Show Specific Myeloid Expression and
Association With Myeloid Immune Activation
In this independent data set, we show high expression of
linc01272 to myeloid dendritic cells (DCs), monocytes (Mo),
peripheral blood mononuclear cells (PBMCs), and neutrophils,
and to a lesser degree to human-derived intestinal tissues and T
cells, but no expression (TPM level < 1 and read count < 10) in B
cells and Caco-2 cells (Fig. 2D). Performing Pearson correlation
analyses (r > 0.75) on those tissues and cells identified 521 genes
that co-expressed with LINC01272. Uunsupervised hierarchical
clustering of this gene set is shown in Fig. 2E, sowing clear separation between myeloid cells and PBMCs from the intestinal
tissues, NK cells, and T cells. Functional annotation enrichment
analyses of those 521 genes (Supplementary Table 5) showed
enrichment for Gene Ontology Biological Process terms involving inflammatory and immune response (P < 1.96E-26) and
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more specifically myeloid functions (P < 4.43E-13) and response
to bacteria (P < 1.68E-10) (Fig. 2F and Supplementary Table 5).
To validate HNF4A-AS1 and LINC01272 cell-specific expression and to test their subcellular localization, we
employed RNA in situ hybridization on paraffin sections using
HNF4A-AS1 antisense Biotin-labeled oligonucleotides probes.
Consistent with the expression data, HNF4A-AS1 is specifically expressed in the epithelia, showing predominantly nuclear
staining in those cells (Fig. 2G). In contrast, LINC01272 show
no expression in epithelia, but are expressed in immune cells
scattered in the intestinal lamina propria (Fig. 2H). Our observations regarding tissue-specific expression of LINC01272 to
leukocytes and HNF4A-AS1 to epithelia are further supported
by the publicly available GTEx RNAseq database, where
HNF4A-AS1 showed the highest expression in small intestine
and liver tissues and LINC01272 showed the highest expression
in whole blood and spleen (Supplementary Fig. 2).

Validation of the Functional Annotation
Enrichment Analyses of HNF4A-AS1 and
LINC01272 lncRNAs Within Our Cohort
To support those lncRNA potential functions and
validate the above co-expression analyses, we employed
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FIGURE 3. Functional annotation enrichment analyses of the HNF4A-AS1 and LINC01272 co-expression networks. A, Functional annotation
enrichment analyses of the HNF4A-AS1 co-expression network using ToppGene/ToppCluster25 and Cytoscape26 are shown. GO: Biological Process
(blue), GO: Pathways (green), GO: Cellular Component (turquoise), and Transcription Factor Binding Site (pink). The full list of gene set enrichment
results and P values is in Supplementary Table 7. B, Functional annotation enrichment analyses of the LINC01272 co-expression network using
ToppGene/ToppCluster25 and Cytoscape26 are shown: GO: Biological Process and GO: Molecular Function (blue) and immune cell (light green)
using the Immunological Genome Project data series through ToppGene/ToppCluster. The full list of gene set enrichment results and P values is in
Supplementary Table 9.

co-expression analyses and functional annotation enrichment
analyses also within our Ctl and inflamed CD ileal samples.
Pearson correlation (r > 0.75) analysis identified 314 downregulated genes that co-express with HNF4A-AS1 (Supplementary
Table 6). Functional annotation of these 314 suppressed genes
(Fig. 3A and Supplementary Table 7) showed enrichment for
entities associated with the organic acid metabolic process
(P < 1.5E-17), lipid metabolic process (P < 2.16E-14), oxidation-reduction process (P < 7.54E-12), vitamin digestion and
absorption (P < 4.67E-7), and brush border cellular component (P < 6.13E-26). Interestingly, functional annotation to
transcription factor binding sites showed top enrichment for
HNF4 (P < 5.6E-4). To model the effect of the inflammatory
signal on prioritized lncRNA in an epithelial model system,
we stimulated Caco-2 cells with IL-1β (25 ng/mL), which were
previously shown to be upregulated in the ileum of patients
with CD17. As expected, we noted an increased expression of
IL8 after incubation with IL-1β. We also detected a significantly increased expression of DUOX2 and decreased expression of APOA1 (Fig. 4), similar to the increased and decreased

expression detected in the ileum of CD patients.17 We further
detected a significant decrease of CDKN2B-AS1, RP11132E11.2, RP11-347E10.1, and RP11-798E3.2 in the Caco-2
system after IL-1β stimulation, as was observed in CD biopsies in comparison with Ctl. Importantly, both CDKN2B-AS1
and HNF4A-AS1 showed enrichment to the nuclear fraction in
the Caco-2 model system like the established nuclear lncRNA
MALAT1, which may suggest a transcriptional regulatory role
in intestinal epithelia (Supplementary Fig. 3).
Pearson correlation analysis identified 187 upregulated genes that co-express with the upregulated LINC01272
(Supplementary Table 8). Functional annotation of these 187
genes (Fig. 3B and Supplementary Table 9) showed enrichment
for entities associated with inflammatory response (P < 2.32E29), response to the molecule of bacterial origin (P < 7.12E26), CD11b activated granulocyte myeloid cells (P < 4.36E-69),
cytokine activity (P < 5.36E-10), and immunoglobulin binding
(P < 2.44E-6). Altogether, combining co-expression and functional enrichment analyses indicated a predominant epithelial-related signature of those downregulated CDKN2B-AS1 and
HNF4A-AS1 co-expressed lncRNAs, in contrast to the granulocyte-associated signature of the upregulated LINC01272.
This was in agreement with our results across a diverse set of
noninflamed tissues and cells (Fig. 2).

HNF4A-AS1 and CDKN2B-AS1 Expression
Significantly Correlates With More Severe
Mucosal Injury

FIGURE 4. Prioritized CD-associated lncRNA and protein-coding genes
are regulated by IL-1β in Caco-2 cells. Caco-2 cells were differentiated
on transwell inserts and were either left untreated or treated with
IL-1β (25 ng/mL) for 24 hours. Prioritized CD-associated downregulated lncRNA and protein-coding mRNA were determined by qPCR of
mRNA. Relative quantification values (Rq) were compared between
IL-1β and untreated cells (n = 6), and log10(Rq) values (mean with SEM)
are presented. Paired t test (1-tailed) was performed on the delta cycle
threshold values (Ct) of specific genes compared with the control gene
GAPDH. *P < 0.05, **P < 0.01, ***P < 0.001.
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We tested for correlation between LINC01272 and
HNF4A-AS1 and clinical disease activity indices and the severity of mucosal injury. Using the Pediatric Crohn’s Disease
Activity Index (PCDAI) as a continuous value or stratifying the iCD group to those inactive (PCDAI ≤ 10), with mild
symptoms (PCDAI ≤ 30), and with moderate-severe symptoms
(PCDAI > 30) at diagnosis showed no significant correlation
or differences, respectively, for both LINC01272 expression
and HNF4A-AS1 expression (Fig. 5). However, dividing the
iCD group into 2 groups based on the presence of deep ulcers
(DU, iCD-DU, and iCD-noDU), which are associated with
endoscopic severity scaling and unfavorable clinical outcome,35
demonstrated a significant increase of LINC01272 in iCD-DU
in comparison with iCD-noDU (Fig. 6). These results are further supported by the significant positive correlation noted
between S100A8 (calprotectin), our best current clinical biomarker for tissue inflammation, and LINC01272 (r = 0.9,
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FIGURE 5. HNF4A-AS1 and LINC01272 lncRNA show no correlation with the Pediatric Crohn’s Disease Activity Index. A, LINC01272 log10(TPM) of
iCD patients (n = 139) were plotted against their Pediatric Crohn’s Disease Activity Index as a continuous value at diagnosis (right) or after stratifying the iCD group to those inactive (n = 12, PCDAI ≤ 10), with mild symptoms (n = 53, PCDAI ≤ 30), and with moderate-severe symptoms (n = 74,
PCDAI > 30) at diagnosis. Log10(TPM) levels of Ctl (n = 38) are shown for comparison. B, HNF4A-AS1 log10(TPM) of iCD patients were plotted against
their PCDAI as a continuous value (right) or after stratifying the group, as in (A). Log10(TPM) levels of Ctl are shown for comparison.

P < 0.001). In contrast, a significant negative correlation
with S100A8 was noted with HNF4A-AS1, and a significant
decrease of HNF4A-AS1 expression was observed in iCD-DU
vs iCD-no DU (Fig. 6). These results emphasize that lncRNAs
show positive correlation with tissue inflammation and lack of
correlation with clinical disease activities (PCDAI). These significant correlations between lncRNA expression and mucosal
tissue injury further highlight the need to elucidate their potential function in CD pathogenesis as a first step toward utilizing
those lncRNAs as targets for potential future interventions.

DISCUSSION
We previously defined a core ileal CD (iCD) signature
enriched for genes coding for innate antimicrobial responses
and a profound loss of nuclear receptor–dependent lipid metabolic functions.17 However, differentially expressed lncRNAs
that may play a central role in regulating the transcriptional
landscape in a tissue-specific manner have not yet been defined.
Growing evidence suggests that lncRNAs contribute to various aspects of gene regulation in the immune system. However,

there are only a few studies focusing on lncRNAs in human
gut pathogenesis,16, 36 and specifically, there are no studies of
the ileum of treatment-naive pediatric CD patients. Here, based
on the largest prospective pediatric treatment-naive inception
cohort, we extend the CD signature to now include 459 differentially expressed lncRNA genes. We show that lncRNA
can be utilized to correctly classify disease or healthy states in
patients undergoing diagnostic endoscopies. Prioritizing differentially expressed genes based on the highest fold change differences, and more uniquely to our study on higher numbers of
co-expressed genes, directed us to epithelial-specific and myeloid-specific lncRNA expression and potential functions. We
validated the lncRNA-specific expression using in situ hybridization in intestinal biopsies. Finally, we captured a significant
correlation between HNF4A-AS1 and LINC01272 expression
and a presence of more severe mucosal ulcers. Those results are
illustrated in Fig. 7. The tissue specificity of lncRNA may offer
a clear interventional advantage as a future pharmacologic target that will have a less off-target toxic effect.
The rapid growth of genome-wide transcriptome data
sets has uncovered a fast-growing list of lncRNAs (>15,000).
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FIGURE 6. HNF4A-AS1 and LINC01272 lncRNA show significant correlation with severity of mucosal injury and with ileal S100A8 gene expression. A,
LINC01272 log10(TPM) of all patients (iCD [n = 139] and Ctl [n = 38]) were plotted against their log10(TPM) of S100A8 as a continuous value (right) or
after stratifying the iCD group to those with or without deep ulcers (iCD-DU [n = 72] and iCD-noDU [n = 67], respectively). B, HNF4A-AS1 log10(TPM)
of all patients plotted against their log10(TPM) of S100A8 as a continuous value (right) or after stratifying the iCD group, as in (A). Analysis of variance with Bonferroni’s multiple comparison test was calculated for the stratified groups, and Pearson correlation was calculated for the continuous
variables. *P < 0.05, **P < 0.01, ***P < 0.001.

However, most of those lncRNAs are uncharacterized, and
their associations with human pathogenesis are only beginning to emerge. LncRNA differential expression in the colon
of adult patients has only recently been associated with CD
and UC using microarray analyses.16, 36 We have been using
RNAseq rather than microarray and propose a pipeline for
lncRNA identification using Ensembl/Gencode annotation
and lncRNA prioritization. Using Ensembl/Gencode annotation, we were able to capture 10 times more lncRNAs than
using the UCSC annotation.17 We show similar altered downregulation of CDKN2B-AS1 and upregulation of LINC01272
in the CD ileum, as was previously reported in the colon of
UC and CD patients16, 36 within our top 15 down- and upregulated lncRNAs and the previously reported downregulation
of DIO3OS (Supplementary Table 2), supporting the validity of our approach. However, we identified HNF4A-AS1,
which shows remarkably high expression specific to the
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small intestine and Caco-2 cells in the enterocytes system,
and we confirmed its expression to predominantly the epithelial nucleus. We also show that 41 differentially expressed
lncRNA genes co-localized with 47 IBD risk variant loci and
are enriched within IBD loci. Those 41 lncRNAs included
our prioritized lncRNAs LINC01272 and HNF4A-AS1.
Interestingly, and unlike previously described data in the
colon of UC patients who show an increase of 329 lncRNAs
and a decrease of 126 lncRNAs in active UC tissues compared with normal controls, we noticed a significantly higher
fraction of the lncRNAs (83% of the total 459 differentially
expressed lncRNA) to be decreased in active ileal CD (iCD)
mucosa in comparison with controls. This observation was
unique to lncRNAs in the ileum as an equal number of protein coding-genes (51%) were downregulated in iCD vs Ctl
(Fig. 2) in the same samples. H19 and SPRY4-IT1 lncRNAs
have both been recently associated with the regulation of
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FIGURE 7. Graphical summary of the cohort and main findings. Using the largest prospective pediatric treatment naïve inception cohort, we
extend the CD signature to now include 459 differentially expressed lncRNA genes. We show that lncRNA can be utilized to correctly classify disease
or healthy states. Prioritizing differentially expressed gene based on highest fold change differences, and more uniquely to our study on higher
number of co-expressed genes, directed us to epithelial-specific and myeloid-specific lncRNA expression and potential functions.

intestinal epithelial barrier function.37, 38 As co-expression
analyses suggest that the downregulated gene signal is coming from the epithelia, it will be highly important to further
understand the role of the remarkably decreased lncRNA
expression on epithelial integrity and repair.
There is a clear necessity in the IBD field for novel drugs
that target major pathogenic pathways with minimal toxicities.
The 12-month remission rate with currently available treatments
is below 65%39 and is associated with increased risk for cancer
and infections. While anti–tumor necrosis factor (anti-TNF)
and newer antibodies offer effective medications, these drugs
substantially increase the economic cost of IBD treatment.
Moreover, at least for anti-TNF treatment, only 50% will maintain long-term remission,40 in part due to development of antidrug antibodies that reduce the effect of the drug. RNA-based
therapies conjugated to cholesterol to facilitate cellular uptake
are currently being evaluated in clinical trials for different disorders including IBD.41, 42 A specific inhibitor of miR-122 showed
prolonged dose-dependent reductions in HCV RNA levels
without evidence of viral resistance,43 and Mongersen, an oral
SMAD7 antisense oligonucleotide, was shown in a double-blind
phase II clinical trial to be efficacious in active CD.42 One

advantage in harnessing lncRNA-directed therapy is its higher
tissue specificity expression in comparison with protein-coding
genes, which should be associated with fewer off-target effects.
Along those lines, we have captured a specific expression of
HNF4A-AS1 to epithelial cells, and LINC01272 to myeloid DC,
monocytes, and neutrophils. Another advantage in targeting
lncRNA is their potential key regulatory role on gene transcription. CDKN2B-AS1 (ANRIL) lncRNA has previously been
shown to regulate gene transcription in cis (in vicinity) and in
trans (at distant loci) in carcinogenesis and cardiovascular disease, whereas the role of the other prioritized lncRNAs is not
yet known and will be tested in future studies. An important
future approach to better characterize lncRNA function will
include employing specific modulations of HNF4A-AS1 and
CDKN2B-AS1 levels. This approach will provide strong evidence of a transcriptional role in intestinal epithelia, which is
more convincing than showing expression alone.
In conclusion, we define differentially expressed lncRNAs
in the ileum of treatment-naive pediatric CD patients. We show
lncRNA utility to correctly classify disease or healthy states in
both discovery and independent validation cohorts. We prioritized lncRNA and confirmed their tissue-specific expression
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and demonstrate their regulation in response to an inflammatory signal in an enterocyte model system. Characterizing
lncRNA expression is the first step toward elucidating lncRNAs’ molecular mechanisms, which will provide further more
comprehensive insights into CD pathogenesis and ultimately
lead to novel therapeutic strategies.
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